PMID- 28697195
OWN - NLM
STAT- MEDLINE
DCOM- 20171005
LR  - 20211204
IS  - 1790-5427 (Print)
IS  - 1790-5427 (Linking)
VI  - 20
IP  - 2
DP  - 2017 May-Aug
TI  - Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: Response to mammalian 
      target of rapamycin inhibitor therapy.
PG  - 169-171
LID - 10.1967/s002449910559 [doi]
AB  - We report on a 27 years old female patient who was referred to our department for 
      whole-body as well as dynamic positron emission tomography/computed tomography 
      (dPET/CT) scan of the upper and middle abdomen with fluorine-18-fluorodeoxy 
      glucose ((18)F-FDG), for further evaluation of a mass in the left adrenal gland 
      region. Positron emission tomography showed a suspicious, enlarged, 
      hypermetabolic mass with an average standardized uptake value (SUV) of 4.5 and a 
      maximum SUV of 5.9. The patient was referred for biopsy, which revealed an 
      angiomyolipoma, a perivascular epithelioid cell tumor (PEComa) of the adrenal 
      gland. Perivascular epithelioid cell tumors are mesenchymal tumors consisting of 
      blood vessels, smooth muscles and fat cells. The patient received 
      anti-proliferative treatment with Afinitor, a mammalian target of rapamycin 
      (mTOR) inhibitor, and was referred again one month after onset of therapy for 
      early response assessment. The follow-up (18)F-FDG PET/CT scan showed a nearly 
      complete resolution of the previously detected adrenal mass, with very low tracer 
      uptake and a decrease in its functional volume. Fluorine- 18-FDG PET/CT can be 
      used for treatment response evaluation of angiomyolipoma treated with 
      mTOR-inhibitors.
FAU - Anwar, Hoda
AU  - Anwar H
AD  - Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 
      Heidelberg, Germany. hoda.nagui@gmail.com.
FAU - Sachpekidis, Christos
AU  - Sachpekidis C
FAU - Schwarzbach, Matthias
AU  - Schwarzbach M
FAU - Dimitrakopoulou-Strauss, Antonia
AU  - Dimitrakopoulou-Strauss A
LA  - eng
PT  - Case Reports
DEP - 20170712
PL  - Greece
TA  - Hell J Nucl Med
JT  - Hellenic journal of nuclear medicine
JID - 101257471
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adrenal Gland Neoplasms/*diagnostic imaging/*drug therapy
MH  - Adult
MH  - Angiomyolipoma/*diagnostic imaging/*drug therapy/pathology
MH  - Everolimus/*administration & dosage
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Radiopharmaceuticals
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2017/07/12 06:00
MHDA- 2017/10/06 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/05/30 00:00 [accepted]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/10/06 06:00 [medline]
PHST- 2017/07/12 06:00 [entrez]
AID - s002449910559 [pii]
AID - 10.1967/s002449910559 [doi]
PST - ppublish
SO  - Hell J Nucl Med. 2017 May-Aug;20(2):169-171. doi: 10.1967/s002449910559. Epub 
      2017 Jul 12.